Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 12/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.78 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.78 |
| ▸ | PGR | P06401 | 2/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.78 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.78 |
| ▸ | HTR1A | P08908 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | GC | P02774 | 1/20 | 0.71 |
| ▸ | RXRA | P19793 | 1/20 | 0.71 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.71 |
| ▸ | CNR1 | P21554 | 1/20 | 0.71 |
| ▸ | HTR2C | P28335 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ercalcitriol SCHEMBL12922723 | 1.00 | VDR (0.80) | VDRADORA3SLC6A2NR1I2PGR | |
| Ercalcitriol SCHEMBL17274136 | 1.00 | VDR (0.80) | VDRADORA3SLC6A2NR1I2PGR | |
| Ercalcitriol SCHEMBL4393978 | 1.00 | VDR (0.80) | VDRADORA3SLC6A2NR1I2PGR | |
| Ercalcitriol SCHEMBL264876 | 1.00 | VDR (0.80) | VDRADORA3SLC6A2NR1I2PGR | |
| Ercalcitriol SCHEMBL264875 | 1.00 | VDR (0.80) | VDRADORA3SLC6A2NR1I2PGR | |
| Ercalcitriol SCHEMBL4398182 | 1.00 | VDR (0.80) | VDRADORA3SLC6A2NR1I2PGR | |
| Ercalcitriol SCHEMBL23142603 | 1.00 | VDR (0.80) | VDRADORA3SLC6A2NR1I2PGR | |
| Ercalcitriol SCHEMBL8776000 | 1.00 | VDR (0.80) | VDRADORA3SLC6A2NR1I2PGR | |
| Ercalcitriol SCHEMBL9050396 | 1.00 | VDR (0.80) | VDRADORA3SLC6A2NR1I2PGR | |
| Ercalcitriol SCHEMBL21433255 | 1.00 | VDR (0.80) | VDRADORA3SLC6A2NR1I2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 691 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3225243-B1 | METHOD OF SAFELY AND EFFECTIVELY TREATING AND PREVENTING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE | OPKO RENAL LLC (US) | 2025-09-03 | — | — | EP | claimed |
| US-20250044305-A1 | LIQUID CHROMATOGRAPHY TANDEM-MASS SPECTROMETRY (LC-MS/MS) ANALYSIS METHOD FOR DETECTING 11 VITAMINS D IN BLOOD | BEIJING HARMONY HEALTH MEDICAL DIAGNOSTICS CO., LTD. (CN) | 2025-02-06 | — | — | US | claimed |
| US-11926583-B2 | Stabilized 1, 25-dihydroxyvitamin D2 and method of making same | EIRGEN PHARMA LTD. (IE) | 2024-03-12 | — | — | US | claimed |
| CN-117147712-A | Liquid chromatography mass spectrometry analysis method for detecting 11 kinds of vitamin D in blood | 北京和合医学诊断技术股份有限公司 | 2023-12-01 | — | — | CN | claimed |
| US-11801275-B2 | Compositions and methods for common colds | M. ALPHABET 3, LLC (US) | 2023-10-31 | — | — | US | claimed |
| US-11752158-B2 | Method of treating vitamin D insufficiency and deficiency | EIRGEN PHARMA LTD. (IE) | 2023-09-12 | — | — | US | claimed |
| EP-3278100-B1 | METHODS AND USES COMPRISING SOLID PHASE EXTRACTION, DERIVATIZATION WITH CROWN ETHERS, AND MASS SPECTROMETRY | TECAN SP INC (US) | 2023-06-14 | — | — | EP | claimed |
| CN-113311080-B | Joint detection method for multiple vitamin D metabolites, detection kit and application thereof | 中国医学科学院北京协和医院 | 2023-02-21 | — | — | CN | claimed |
| CN-113631272-B | Compositions, devices and methods for mitigating lipoprotein interference in vitro diagnostic assays for hydrophobic analytes | 美国西门子医学诊断股份有限公司 | 2022-12-20 | — | — | CN | claimed |
| US-11513132-B2 | Solid phase extraction, derivatization with crown ethers, and mass spectrometry, methods, reagents and kits | TECAN SP, INC. (US) | 2022-11-29 | — | — | US | claimed |
| WO-2001042205-A2 | TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH VITAMIN D COMPOUNDS | THE PENN STATE RESEARCH FOUNDATION (US) | 2001-06-14 | — | — | WO | claimed |
| US-6242435-B1 | VITAMIN D ANALOG AND A RETINOID | GENTRIX LLC | 2001-06-05 | — | — | US | claimed |
| US-20010002396-A1 | COMPOSITIONS AND METHODS OF TREATING SKIN CONDITIONS | GENTRIX LLC | 2001-05-31 | — | — | US | claimed |
| EP-0587751-A1 | THERAPEUTIC COMPOSITIONS FOR OSTEOINDUCTION | THE PROCTER & GAMBLE COMPANY (US) | 1994-03-23 | — | — | EP | claimed |
| EP-0112332-B1 | VITAMIN D GLYCOSIDES | THE GENERAL HOSPITAL CORPORATION (US) | 1993-06-16 | — | — | EP | claimed |
| WO-1992021365-A1 | THERAPEUTIC COMPOSITIONS FOR OSTEOINDUCTION | THE PROCTER & GAMBLE COMPANY (US) | 1992-12-10 | — | — | WO | claimed |
| EP-0042673-B1 | CYTORECEPTOR ASSAY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1986-03-26 | — | — | EP | claimed |
| WO-1982000059-A1 | CYTORECEPTOR ASSAY | UNIV CALIFORNIA (US) | 1982-01-07 | — | — | WO | claimed |
| EP-0042673-A1 | Cytoreceptor assay | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1981-12-30 | — | — | EP | claimed |
| US-4225596-A | Method for treating calcium imbalance and improving calcium absorption in mammals | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1980-09-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11513132-B2 | Solid phase extraction, derivatization with crown ethers, and mass spectrometry, methods, reagents and kits | CYP2C8, CES2, UGT1A8 | VDR 1881/4885ADORA3 3939/4885SLC6A2 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.